<DOC>
	<DOCNO>NCT01331109</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy milnacipran pediatric patient age 13 17 year primary fibromyalgia .</brief_summary>
	<brief_title>Long-Term Safety Efficacy Study Milnacipran Pediatric Patients With Primary Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Patients must complete discontinue prematurely leadin study , MLNMD14 , tolerate minimum daily dose 50mg milnacipran Can tolerate minimum daily dose 50mg milnacipran Significant risk suicidality Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Pediatric Fibromyalgia</keyword>
	<keyword>Adolescent Fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>Savella</keyword>
	<keyword>loss therapeutic response</keyword>
	<keyword>Forest Research Institute</keyword>
	<keyword>Pain</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Serotonin Norepinephrine Reuptake Inhibitors</keyword>
</DOC>